Profound Medical Corp. (TSE:PRN) Director Buys C$143,319.75 in Stock

Profound Medical Corp. (TSE:PRN) Director Arun Menawat Dr. acquired 14,200 shares of the company’s stock in a transaction that occurred on Friday, March 14th. The shares were acquired at an average cost of C$10.09 per share, for a total transaction of C$143,319.75.

Profound Medical Trading Down 3.6 %

TSE:PRN opened at C$9.67 on Friday. Profound Medical Corp. has a one year low of C$7.90 and a one year high of C$15.75. The company has a debt-to-equity ratio of 20.05, a current ratio of 6.12 and a quick ratio of 14.98. The company’s 50-day simple moving average is C$9.84 and its 200 day simple moving average is C$10.46. The firm has a market capitalization of C$203.77 million, a P/E ratio of -5.02 and a beta of 0.81.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.